Press Releases

All Releases
View Summary Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Dec 4, 2013
PDF 20.1 KB Add to Briefcase
View Summary Myriad Genetics Announces Second HRD Collaboration
Nov 20, 2013
PDF 15.8 KB Add to Briefcase
View Summary Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
Nov 12, 2013
PDF 16.7 KB Add to Briefcase
View Summary Myriad Genetics to Present at the 2013 Credit Suisse Annual Healthcare Conference
Nov 8, 2013
PDF 11.7 KB Add to Briefcase
View Summary Myriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014
Nov 5, 2013
PDF 26.1 KB Add to Briefcase
View Summary Myriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists
Oct 29, 2013
PDF 16.6 KB Add to Briefcase
View Summary Myriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study
Oct 28, 2013
PDF 17.1 KB Add to Briefcase
View Summary Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
Oct 24, 2013
PDF 23.7 KB Add to Briefcase
View Summary Myriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013
Oct 23, 2013
PDF 12.7 KB Add to Briefcase
View Summary Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
Oct 14, 2013
PDF 17.3 KB Add to Briefcase
View Summary Myriad Genetics Study Highlights Importance of myRisk(TM) Hereditary Cancer Testing
Oct 9, 2013
PDF 18.0 KB Add to Briefcase
View Summary Myriad's myRisk Hereditary Cancer(TM) Test Improves Colon Cancer Testing by 60 Percent
Oct 7, 2013
PDF 20.0 KB Add to Briefcase
View Summary Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3
Oct 1, 2013
PDF 16.4 KB Add to Briefcase
View Summary Myriad Genetics' myPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint
Sep 25, 2013
PDF 17.1 KB Add to Briefcase
View Summary Myriad Genetics to Present at the Morgan Stanley Global Healthcare Conference
Sep 5, 2013
PDF 11.8 KB Add to Briefcase
View Summary Myriad Genetics Launches myRisk(TM) Hereditary Cancer Panel
Sep 5, 2013
PDF 16.1 KB Add to Briefcase
View Summary Myriad Genetics Expands Collaboration with AstraZeneca on Olaparib Phase 3 Clinical Trials
Sep 4, 2013
PDF 16.5 KB Add to Briefcase
View Summary Myriad Genetics Reports Full-Year and Fiscal Fourth-Quarter 2013 Financial Results
Aug 13, 2013
PDF 28.8 KB Add to Briefcase
View Summary Myriad Genetics Announces Date of Full-Year and Fourth-Quarter Fiscal 2013 Financial Results Conference Call
Jul 30, 2013
PDF 12.4 KB Add to Briefcase
View Summary Myriad Expands Its Patient Financial Assistance Program
Jul 15, 2013
PDF 16.0 KB Add to Briefcase
Showing 21-40 of 293 Page: 1 2 3 4 5 6 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ:MYGN)

Price:
37.42
Change:
- 0.55
Open:
38.34
Previous Close:
37.97
Day High:
38.34
Day Low:
37.41
52 Week High:
42.50
52 Week Low:
20.02
Volume:
113,500
10:27 AM ET on Apr 21, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com